Sarepta Therapeutics (NASDAQ:SRPT) Given New $226.00 Price Target at Barclays

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective hoisted by Barclays from $185.00 to $226.00 in a research report released on Friday morning, Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on SRPT. Cantor Fitzgerald reaffirmed a neutral rating and issued a $128.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. Mizuho increased their price objective on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a buy rating in a report on Friday, May 17th. BMO Capital Markets reissued an outperform rating and set a $170.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 14th. Citigroup increased their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a buy rating in a research note on Thursday, February 29th. Finally, Robert W. Baird boosted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an outperform rating in a research note on Friday. Four analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $184.83.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $163.85 on Friday. The company has a 50-day moving average price of $126.47 and a two-hundred day moving average price of $120.71. The stock has a market cap of $15.49 billion, a price-to-earnings ratio of 1,489.55 and a beta of 0.96. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same period last year, the firm earned ($1.44) EPS. The firm’s revenue was up 63.1% compared to the same quarter last year. Analysts forecast that Sarepta Therapeutics will post 2.99 EPS for the current year.

Insider Activity

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRPT. Capital Fund Management S.A. acquired a new position in Sarepta Therapeutics in the 4th quarter worth about $7,299,000. Vanguard Group Inc. grew its stake in shares of Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company’s stock valued at $1,039,212,000 after buying an additional 41,465 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Sarepta Therapeutics in the fourth quarter worth approximately $777,000. Principal Financial Group Inc. raised its position in Sarepta Therapeutics by 125.3% during the fourth quarter. Principal Financial Group Inc. now owns 49,539 shares of the biotechnology company’s stock valued at $4,777,000 after acquiring an additional 27,549 shares in the last quarter. Finally, Great Point Partners LLC lifted its stake in Sarepta Therapeutics by 14.0% in the fourth quarter. Great Point Partners LLC now owns 80,000 shares of the biotechnology company’s stock valued at $7,714,000 after acquiring an additional 9,800 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.